These results suggest that serum HMGB1 could potentially serve as a valuable blood-based biomarker for prognostic stratification, allowing clinicians to identify individuals with ischemic stroke who are at higher risk of experiencing cognitive deterioration in the short-term following the event. This evidence concerns the gene HMGB1 and ischemic stroke.